HS022

· Zhejiang Hisun Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HS022, covering 2023-10-30 to 2023-10-30. Get the full timeline:

Most recent: Clinical Trial Update: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer [Phase 3]

See pricing